Clinical Trials on HER2-positive Gastric/Gastroesophageal Junction Cancer

Total 1078 results

Triumvira Immunologics, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2)

HER2 Positive Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction Cancer

United States, Canada
Bavarian Nordic

Active, not recruiting

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Chordoma | HER2-positive Breast Cancer | HER2-positive Gastric/Gastroesophageal Junction Cancer

United States
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
MacroGenics
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)

Gastric Cancer | Gastroesophageal Junction Cancer | HER2-positive Gastric Cancer

Korea, Republic of, United States, China, Italy, Taiwan, Germany, Singapore, United Kingdom, Poland
BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
Precirix

Terminated

A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment

United States, Canada
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Locally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Charite University, Berlin, Germany

Not yet recruiting

Establishment of 2D and 3D Primary Cell Cultures From Gastric and Gastroesophageal Junction Cancer

Gastric and Gastroesophageal Junction Cancer

Germany
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Junction Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

China
GeneScience Pharmaceuticals Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaborators

Unknown

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Advanced Gastric or Gastroesophageal Junction Cancer

China
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
AIPING ZHOU

Not yet recruiting

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Immunotherapy | Sintilimab | Locally Advanced Solid Tumor | Oxaliplatin | HER2-positive | Gastric or Gastroesophageal Junction Adenocarcinoma | S-1

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage 0 Gastric... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Not yet recruiting

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant... and other conditions

United States
Celularity Incorporated

Active, not recruiting

CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Metastatic HER2 Positive Gastroesophageal Junction Cancer

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

China
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Peritoneal Carcinomatosis | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Terminated

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Gastric Cancer | Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Junction Cancer | Gastric Tumor | Gastroesophageal Junction Adenocarcinoma | GastroEsophageal Cancer | Esophageal Tumor | Esophagogastric Tumors | Gastroesophageal Junction Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Washington University School of Medicine
Molecular Templates, Inc.

Withdrawn

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

HER2-positive Solid Tumor | HER-2 Positive Cancer
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

United States, Germany
National Cancer Institute (NCI)

Recruiting

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric... and other conditions

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (INTEGA)

Gastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric Cancer

Germany
QuantumLeap Healthcare Collaborative
Byondis B.V.

Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Ovarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditions

United States
Mersana Therapeutics

Recruiting

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast Cancer

United States
Nanfang Hospital, Southern Medical University

Completed

JNT Versus TNT to Guided OGT-overlap Oesophagojejunostomy

Gastric/Gastroesophageal Junction (g/Gej) Cancer

China
Ukrainian Society of Clinical Oncology

Recruiting

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR)

Stomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction Adenocarcinoma

Ukraine
Shen Lin
RemeGen Co., Ltd.

Not yet recruiting

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Advanced Solid Tumor | Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma | HER2

China
Yu jiren

Recruiting

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

HER2-positive Gastric Cancer | Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction

China
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Amsterdam UMC, location VUmc
AstraZeneca

Recruiting

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study (HER Image)

Breast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Cancer

Netherlands
National Cancer Institute (NCI)

Not yet recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
Orum Therapeutics USA, Inc.

Recruiting

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

United States
Suzhou Transcenta Therapeutics Co., Ltd.
Bristol-Myers Squibb

Recruiting

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Cancer | Advanced Cancer | Gastroesophageal-junction Cancer

United States
Astellas Pharma Global Development, Inc.

Completed

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer (PILOT)

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric Adenocarcinoma

Germany, Latvia
Astellas Pharma Global Development, Inc.

Completed

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer (FAST)

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric Adenocarcinoma

Bulgaria, Czechia, Germany, Latvia, Russian Federation, Ukraine
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic... and other conditions

United States
Hoffmann-La Roche

Completed

Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma

Gastric Cancer, Gastroesophageal Junction Cancer

France
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
xiaohua li

Not yet recruiting

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Gastroesophageal Junction Cancer
Rigshospitalet, Denmark
Danish Cancer Society

Completed

Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer

Gastroesophageal-junction Cancer

Denmark

Clinical Trials on HER2-positive Gastric/Gastroesophageal Junction Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations